NantWorks, Sorrento to discover and develop new anti-cancer immunotherapies
The new products will be developed from Sorrento’s G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks’ pan-omics based, precision medicine approach. As part of the deal,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.